B7-33 is a simplified, single-chain analog of human relaxin-2, designed to retain RXFP1 receptor activation while being easier and cheaper to manufacture than the native two-chain hormone. It shows vasodilatory and anti-fibrotic properties in preclinical models.
Category: Cardiovascular / Research. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical research
B7-33 activates RXFP1 receptors, triggering vasodilation via nitric oxide pathway activation and anti-fibrotic signaling through MMP upregulation for ECM remodeling. Unlike full relaxin-2, it is a single-chain peptide that is simpler to synthesize.
Safety considerations: No human safety data available; Theoretical risk of hypotension.
Reviewed by the PeptideAtlas Editorial Team.
| Production method | synthetic |
|---|---|
| Anti-doping status | not-listed |
Serelaxin (recombinant relaxin-2) is a two-chain peptide that failed Phase III trials for heart failure. B7-33 was designed as a simpler, single-chain alternative that retains RXFP1 activity.
B7-33 is a simplified, single-chain analog of human relaxin-2, designed to retain RXFP1 receptor activation while being easier and cheaper to manufacture than the native two-chain hormone. It shows vasodilatory and anti-fibrotic properties in preclinical models.
On the PeptideAtlas A–F scale, B7-33 is rated D (Preclinical Only). Mostly animal or preclinical evidence
Preclinical research
B7-33 activates RXFP1 receptors, triggering vasodilation via nitric oxide pathway activation and anti-fibrotic signaling through MMP upregulation for ECM remodeling. Unlike full relaxin-2, it is a single-chain peptide that is simpler to synthesize.